The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
Open accessAbstract
The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has resulted in a significant market ‘boom’, garnering worldwide attention. Despite ADCs presenting huge challenges to researchers, particularly regarding the identification of a suitable combination of antibody, linker, and payload, as of September 2021, 11 ADCs have been granted FDA approval, with eight of these approved since 2017 alone. Optimism for this therapeutic approach is clear, despite the COVID-19 pandemic, 2020 was a landmark year for deals and partnerships in the ADC arena, suggesting that there remains significant interest from Big Pharma. Herein we review the enthusiasm for ADCs by focusing on the features of those approved by the FDA, and offer some thoughts as to where the field is headed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Improved protein structure prediction using potentials from deep learning
Senior, A. W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., Qin, C., Žídek, A., Nelson, A. W. R., Bridgland, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1923-7 · Cited by 3,378
IgG Subclasses and Allotypes: From Structure to Effector Functions
Vidarsson, G., Dekkers, G., & Rispens, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00520 · Cited by 2,667
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
A History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,970
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028485 · Cited by 1,711
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Virtual screening of chemical libraries
Shoichet, B. K. (2004) · Nature · doi:10.1038/nature03197 · Cited by 1,425
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O’Brien, S., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,413
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004413 · Cited by 1,333
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Powles, T., Rosenberg, J. E., Sonpavde, G. P., Loriot, Y., Durán, I., Lee, J.-L., Matsubara, N., Vulsteke, C., Castellano, D., Wu, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035807 · Cited by 1,229
Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,177
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Ashley, E. A. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.86 · Cited by 1,116
Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 997
Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 815
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illés, Á., Picardi, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708984 · Cited by 789
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn, L. H., Herrera, A. F., Flowers, C. R., Kamdar, M. K., McMillan, A., Hertzberg, M., Assouline, S., Kim, T. M., Kim, W. S., Ozcan, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00172 · Cited by 774
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Senter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763
Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Gianni, A. M., Carella, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60165-9 · Cited by 742
Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., Raitano, A., Nadell, R., Liu, W., Lortie, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1313 · Cited by 724
Cleavable linkers in antibody–drug conjugates
Bargh, J. D., Isidro-Llobet, A., Parker, J. S., & Spring, D. R. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00676h · Cited by 652
Rosenberg, J. E., O’Donnell, P. H., Balar, A. V., McGregor, B. A., Heath, E. I., Yu, E. Y., Galsky, M. D., Hahn, N. M., Gartner, E. M., Pinelli, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01140 · Cited by 642
Petersdorf, S. H., Kopecky, K. J., Slovak, M., Willman, C., Nevill, T., Brandwein, J., Larson, R. A., Erba, H. P., Stiff, P. J., Stuart, R. K., et al. (2013) · Blood · doi:10.1182/blood-2013-01-466706 · Cited by 638
Trastuzumab emtansine: mechanisms of action and drug resistance
Barok, M., Joensuu, H., & Isola, J. (2014) · Breast Cancer Research · doi:10.1186/bcr3621 · Cited by 595
Yamane‐Ohnuki, N., Kinoshita, S., Inoue‐Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20151 · Cited by 572
From big data analysis to personalized medicine for all: challenges and opportunities
Alyass, A., Turcotte, M., & Meyre, D. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0108-y · Cited by 557
Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., & Trail, P. A. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025536j · Cited by 555
Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
Lambert, J. M., & Chari, R. V. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500766w · Cited by 545
Tagawa, S. T., Balar, A. V., Petrylak, D. P., Kalebasty, A. R., Loriot, Y., Fléchon, A., Jain, R. K., Agarwal, N., Bupathi, M., Barthelemy, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03489 · Cited by 543
Pastan, I., Hassan, R., FitzGerald, D. J., & Kreitman, R. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1891 · Cited by 528
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
Peters, C., & Brown, S. (2015) · Bioscience Reports · doi:10.1042/bsr20150089 · Cited by 492
Gamis, A. S., Alonzo, T. A., Meshinchi, S., Sung, L., Gerbing, R. B., Raimondi, S. C., Hirsch, B. A., Kahwash, S. B., Heerema-McKenney, A., Winter, L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3628 · Cited by 486
Tai, Y.-T., Mayes, P. A., Acharya, C., Zhong, M. Y., Cea, M., Cagnetta, A., Craigen, J., Yates, J., Gliddon, L., Fieles, W., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535088 · Cited by 484
Site-selective modification strategies in antibody–drug conjugates
Walsh, S. J., Bargh, J. D., Dannheim, F. M., Hanby, A. R., Seki, H., Counsell, A. J., Ou, X., Fowler, E., Ashman, N., Takada, Y., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00310g · Cited by 461
Jain, N., Smith, S. W., Ghone, S., & Tomczuk, B. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1657-7 · Cited by 459
Caimi, P. F., Ai, W., Alderuccio, J. P., Ardeshna, K. M., Hamadani, M., Hess, B., Kahl, B. S., Radford, J., Solh, M., Stathis, A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00139-x · Cited by 441
Coleman, R. L., Lorusso, D., Gennigens, C., González-Martín, A., Randall, L., Cibula, D., Lund, B., Woelber, L., Pignata, S., Forget, F., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00056-5 · Cited by 410
Potent antibody drug conjugates for cancer therapy
Senter, P. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.023 · Cited by 401
Cathepsin B as a cancer target
Gondi, C. S., & Rao, J. S. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.740461 · Cited by 399
Analytical methods for physicochemical characterization of antibody drug conjugates
Wakankar, A., Chen, Y., Gokarn, Y., & Jacobson, F. S. (2011) · mAbs · doi:10.4161/mabs.3.2.14960 · Cited by 382
Amadori, S., Suciu, S., Selleslag, D., Aversa, F., Gaidano, G., Musso, M., Annino, L., Venditti, A., Voso, M. T., Mazzone, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0060 · Cited by 362
DiJoseph, J. F., Armellino, D. C., Boghaert, E. R., Khandke, K., Dougher, M. M., Sridharan, L., Kunz, A., Hamann, P. R., Gorovits, B., Udata, C., et al. (2004) · Blood · doi:10.1182/blood-2003-07-2466 · Cited by 361
Palanca-Wessels, M. C. A., Czuczman, M., Salles, G., Assouline, S., Sehn, L. H., Flinn, I., Patel, M. R., Sangha, R., Hagenbeek, A., Advani, R., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70128-2 · Cited by 336
Pereira, N. A., Chan, K. F., Lin, P. C., & Song, Z. (2018) · mAbs · doi:10.1080/19420862.2018.1466767 · Cited by 334
Ritchie, M., Tchistiakova, L., & Scott, N. (2013) · mAbs · doi:10.4161/mabs.22854 · Cited by 312
Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., & Goldenberg, D. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2939 · Cited by 311
Sacituzumab Govitecan: First Approval
Syed, Y. Y. (2020) · Drugs · doi:10.1007/s40265-020-01337-5 · Cited by 293
Junutula, J. R., Flagella, K. M., Graham, R. A., Parsons, K. L., Ha, E., Raab, H., Bhakta, S., Nguyen, T., Dugger, D. L., Li, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0987 · Cited by 292
Yu, E. Y., Petrylak, D. P., O'Donnell, P. H., Lee, J.-L., van der Heijden, M. S., Loriot, Y., Stein, M. N., Necchi, A., Kojima, T., Harrison, M. R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00094-2 · Cited by 287
Human Antibody Effector Function
Burton, D. R., & Woof, J. M. (1992) · Advances in Immunology · doi:10.1016/s0065-2776(08)60486-1 · Cited by 265
Antibody–drug conjugates in solid tumors: a look into novel targets
Criscitiello, C., Morganti, S., & Curigliano, G. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01035-z · Cited by 250
Hinman, L. M., Hamann, P. R., Wallace, R., Menendez, A. T., Durr, F. E., & Upeslacis, J. (1993) · PubMed · Cited by 236
Antibody–drug conjugates for cancer: poised to deliver?
Hughes, B. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3270 · Cited by 188
Targeting B-Cell Maturation Antigen in Multiple Myeloma
Tai, Y.-T., & Anderson, K. C. (2015) · Immunotherapy · doi:10.2217/imt.15.77 · Cited by 188
Hoffmann, R. M., Coumbe, B. G. T., Josephs, D. H., Mele, S., Ilieva, K. M., Cheung, A., Tutt, A. N., Spicer, J. F., Thurston, D. E., Crescioli, S., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1395127 · Cited by 188
ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies
Zammarchi, F., Corbett, S., Adams, L., Tyrer, P. C., Kiakos, K., Janghra, N., Marafioti, T., Britten, C. E., Havenith, C. E. G., Chivers, S., et al. (2018) · Blood · doi:10.1182/blood-2017-10-813493 · Cited by 181
Younes, A., Yasothan, U., & Kirkpatrick, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3629 · Cited by 170
Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics
Waight, A. B., Bargsten, K., Doronina, S., Steinmetz, M. O., Sussman, D., & Prota, A. E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0160890 · Cited by 167
Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components
Dosio, F., Brusa, P., & Cattel, L. (2011) · Toxins · doi:10.3390/toxins3070848 · Cited by 166
Kostova, V., Désos, P., Starck, J.-B., & Kotschy, A. (2021) · Pharmaceuticals · doi:10.3390/ph14050442 · Cited by 158
Naito, K., Takeshita, A., Shigeno, K., Nakamura, S., Fujisawa, S., Shinjo, K., Yoshida, H., Ohnishi, K., Mori, M., Terakawa, S., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401851 · Cited by 153
Belantamab Mafodotin: First Approval
Markham, A. (2020) · Drugs · doi:10.1007/s40265-020-01404-x · Cited by 145
Molecular mechanisms of late endosome morphology, identity and sorting
Russell, M. R. G., Nickerson, D. P., & Odorizzi, G. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.06.002 · Cited by 128
Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer
Ford, C. H. J., Newman, C. E., Johnson, J. R., et al. (1983) · British Journal of Cancer · doi:10.1038/bjc.1983.4 · Cited by 118
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
Oflazoglu, E., Stone, I. J., Gordon, K. A., Grewal, I. S., van Rooijen, N., Law, C., & Gerber, H. (2007) · Blood · doi:10.1182/blood-2007-06-097014 · Cited by 117
High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody–Drug Conjugates
de Goeij, B. E. C. G., Satijn, D. P. E., Freitag, C. M., Wubbolts, R., Bleeker, W. K., Khasanov, A. B., Zhu, T., Chen, G., Miao, D., van Berkel, P. H. C., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0798 · Cited by 99
Mazor, R., & Pastan, I. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01261 · Cited by 94
The oncology market for antibody–drug conjugates
do Pazo, C., Nawaz, K., & Webster, R. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/d41573-021-00054-2 · Cited by 93
Machine Learning To Predict Cell-Penetrating Peptides for Antisense Delivery
Wolfe, J. M., Fadzen, C. M., Choo, Z.-N., Holden, R. L., Yao, M., Hanson, G. J., & Pentelute, B. L. (2018) · ACS Central Science · doi:10.1021/acscentsci.8b00098 · Cited by 85
Tapping into the drug discovery potential of AI
Savage, N. J. (2021) · Biopharma Dealmakers · doi:10.1038/d43747-021-00045-7 · Cited by 79
Freedman, D. H. (2019) · Nature · doi:10.1038/d41586-019-03846-0 · Cited by 65
Deep Learning for Prediction and Optimization of Fast-Flow Peptide Synthesis
(2020) · doi:10.1021/acscentsci.0c00979 · Cited by 61
Targeted Therapy With Immunoconjugates for Multiple Myeloma
Bruins, W. S. C., Zweegman, S., Mutis, T., & van de Donk, N. W. C. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01155 · Cited by 60
Renneville, A., Abdelali, R. B., Chevret, S., Nibourel, O., Cheok, M. H.-C., Pautas, C., Duléry, R., Boyer, T., Cayuela, J., Hayette, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1536 · Cited by 55
The Evolution of Antibody-Drug Conjugates: A Positive Inflexion Point
Tolcher, A. W. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_281103 · Cited by 48
Humanization by CDR Grafting and Specificity-Determining Residue Grafting
Kim, J., & Hong, H. J. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-974-7_13 · Cited by 39
Pushing the Envelope: Advancement of ADCs Outside of Oncology
McPherson, M. J., & Hobson, A. D. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9929-3_2 · Cited by 37
Photochemical Activation of Enediyne Warheads: A Potential Tool for Targeted Antitumor Therapy
Bhattacharya, P., Basak, A., Campbell, A., & Alabugin, I. V. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00911 · Cited by 32
Introduction to Antibody–Drug Conjugates (ADCs)
Pysz, I., Jackson, P. J., & Thurston, D. E. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788012898-00001 · Cited by 27
Humanising Antibodies by CDR Grafting
Williams, D. G., Matthews, D. J., & Jones, T. (2010) · Springer eBooks · doi:10.1007/978-3-642-01144-3_21 · Cited by 27
Analytical techniques for the characterization of Antibody Drug Conjugates: Challenges and prospects
Neupane, R., & Bergquist, J. (2017) · European Journal of Mass Spectrometry · doi:10.1177/1469066717733919 · Cited by 21
Fernández‐Codina, A., Nevskaya, T., Baron, M. G., Appleton, C. T., Cecchini, M. J., Philip, A., El-Shimy, M., Vanderhoek, L., Pinal‐Fernandez, I., & Pope, J. E. (2024) · Lara D. Veeken · doi:10.1093/rheumatology/keae235 · Cited by 18
Auristatin Payloads for Antibody–Drug Conjugates (ADCs)
Doronina, S. O., & Senter, P. D. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788012898-00073 · Cited by 5
Miura, K. (2017) · Journal of Nihon University Medical Association · doi:10.4264/numa.76.1_15 · Cited by 1
Kumar, A., White, J., Christie, R. J., Dimasi, N., & Gao, C.-S. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.08.002 · Cited by 1
Cited by
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
Suehnholz, S. P., Nissan, M. H., Zhang, H., Kundra, R., Nandakumar, S., Lu, C., Carrero, S., Dhaneshwar, A., Fernandez, N., Xu, B. W., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0467 · Cited by 401
Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance
Zhang, A., Miao, K., Sun, H., & Deng, C.-X. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72534 · Cited by 352
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies
Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108206 · Cited by 67
Yin, X., Zhuang, Y., Song, H., Xu, Y., Zhang, F., Cui, J., Zhao, L., Yu, Y., Zhang, Q., Ye, J., et al. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.11.002 · Cited by 9
Metadata
- Authors
- Tong, J. T. W., Harris, P. W. R., Brimble, M. A., & Kavianinia, I.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2021-09-27
- Volume
- 26
- Issue
- 19
- Pages
- 5847
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3204247219
- Cited by
- 287
- References
- 103
- FWCI
- 26.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.